Type 1 Diabetes and Other Non-Approved Uses Tirzepatide is approved by the FDA for managing type 2 diabetes and aiding weight loss
Current data suggest that when chyme enters the duodenum it triggers GIP release in the proximal gut
No significant difference was found in the primary outcome of general distribution of total hangover scores
/assets/production/practices/8374cadb2253e5496cfee3ef82ab5175a5e6343b/images/2820189.png)
Contact your GP or prescriber promptly if you experience: Diarrhoea lasting more than 4872 hours without improvement Signs of dehydration, including dark urine, dizziness, dry mouth, or reduced urination dehydration can lead to acute kidney injury, particularly in people with pre-existing kidney conditions Blood or mucus in your stools, or rectal bleeding Severe or worsening abdominal pain, particularly if localised, persistent, or accompanied by fever Persistent vomiting that prevents you from keeping fluids down Rapid, symptomatic, or disproportionate weight loss accompanied by systemic symptoms such as fatigue or fever this is distinct from the expected gradual weight loss associated with treatment and should be discussed with your prescriber Symptoms that are substantially affecting your ability to work, sleep, eat, or carry out daily activities Seek urgent medical assessment if you develop: Severe, persistent abdominal pain particularly pain radiating to the back which may indicate pancreatitis
